Literature DB >> 8082675

Gene therapy prospects for Duchenne muscular dystrophy.

P R Clemens1, C T Caskey.   

Abstract

Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disorder caused by mutations in the dystrophin gene. The lack of adequate therapy for this disease provides impetus for the development of gene therapy strategies. A recombinant dystrophin cDNA and animal models of the disease are available for this therapy development. Characterization of these reagents and current progress toward gene therapy for DMD will be described.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082675     DOI: 10.1159/000117035

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

1.  Sickle cell screening policies as portent: how will the human genome project affect public sector genetic services?

Authors:  D D Phoenix; S M Lybrook; R W Trottier; F C Hodgin; L A Crandall
Journal:  J Natl Med Assoc       Date:  1995-11       Impact factor: 1.798

Review 2.  Advances in neurology.

Authors:  C R Kennedy
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

3.  The clinical and molecular genetic approach to Duchenne and Becker muscular dystrophy: an updated protocol.

Authors:  A J van Essen; A L Kneppers; A H van der Hout; H Scheffer; I B Ginjaar; L P ten Kate; G J van Ommen; C H Buys; E Bakker
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

4.  Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect.

Authors:  Jay J Han; Gregorij Kurillo; Richard T Abresch; Evan De Bie; Alina Nicorici; Ruzena Bajcsy
Journal:  Muscle Nerve       Date:  2015-06-03       Impact factor: 3.217

5.  Duchenne Muscular Dystrophy.

Authors:  Susan T. Iannaccone; Zohair Nanjiani
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.